Drug intelligence / Profile preview

Oleuropein

Development stage
Phase 3
Modality
Small Molecules
Administration
Oral
01

Overview

Oleuropein is a phenolic compound found primarily in olive leaves and olive oil, recognized as a key bioactive constituent of the Mediterranean diet. It exhibits multiple pharmacological properties, including potent antioxidant, anti-inflammatory, antihypertensive (blood pressure-lowering), cardioprotective, neuroprotective, anti-atherogenic, anticancer, and antimicrobial effects[1][4][5]. Mechanistically, oleuropein acts as a free radical scavenger and modulates oxidative stress by inhibiting reactive oxygen species (ROS) production and increasing inducible nitric oxide synthase (iNOS) expression[4][6]. It also inhibits the mammalian target of rapamycin (mTOR) pathway and promotes autophagy[1], which may underlie its protective effects in neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease by preventing toxic protein aggregation[1]. Oleuropein has been shown to inhibit human epidermal growth factor receptor 2 (HER2), relevant in breast cancer cells[1], induce apoptosis in cancer cell lines[4], lower cholesterol levels through synergistic action with other olive leaf constituents[5], improve insulin sensitivity via hypoglycemic effects[5], and exert vasodilatory actions independent of vascular endothelium integrity. Its main metabolite is hydroxytyrosol. While widely available as an ingredient in dietary supplements—often marketed as "olive leaf extract"—oleuropein itself is not an approved pharmaceutical drug for any indication.

Other names
oleuropein
02

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)NOS2 (Nitric Oxide Synthase 2)mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on Oleuropein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oleuropein.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call